Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
AM6545
Cat. No.:
OB0425LY-034
Appearance:
Solid
Purity:
98.3%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
AM6545 is a CB2 cannabinoid receptor antagonist involved in the modulation of pain and metabolism.
Synonyms:
1245626-05-4; AM 6545; AM-6545; 5-[4-(4-Cyanobut-1-yn-1-yl)phenyl]-1-(2,4-dichlorophenyl)-N-(1,1-dioxo-1lambda~6~,4-thiazinan-4-yl)-4-methyl-1H-pyrazole-3-carboxamide; 5-[4-(4-Cyanobut-1-ynyl)phenyl]-1-(2,4-dichlorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-methylpyrazole-3-carboxamide
CAS No.:
1245626-05-4
Compound CID:
46912919
Formula:
C26H23Cl2N5O3S
Formula Weight:
556.46
Specification
Target:
Cannabinoid receptor
Pathway:
GPCR/G protein; Neuronal signaling
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
AM6545 can be used to study biological mechanisms related to pain management and obesity.
